drugset / Trial / NCT00098033

Investigation of Clofarabine in Acute Leukemias

NCT00098033

Phase 2 Completed 64 enrolled University of Texas
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The goals and objectives of this project are to evaluate the antileukemic activity of the investigational agent clofarabine in patients with acute myelogenous leukemia (AML), acute lymphocytic leukemia (ALL), and chronic myelogenous leukemia (CML) in accelerated and blastic phases.

Timeline

Start
2002-09
Primary completion
Completion
2005-09

Publications

  • Background Cortes JE, Gandhi V, et al. Clofarabine (2-chloro-9-(deoxy-2-fluoro-b-D-arabinosfuranosyl)adenine) is active for patients with refractory or relapsed acute leukemia. #739 ASH 2002.

Drugs

EvaluationDrugModalityDoseRoute
Subject Clofarabine Other / unclassified